Cardiol Therapeutics Presents Phase II MAVERIC Pilot Clinical Results for Recurrent Pericarditis at American Heart Association Scientific Sessions 2024

Prossionally Educated: The Impact of CardiolRx™ on Pericarditis Treatment Marked and Rapid Reductions in Pericarditis Pain and Inflammation Cardiol Therapeutics Inc. has recently reported promising results from its Phase II open-label MAvERIC-Pilot study, which focused on the effects of CardiolRx™ on patients with symptomatic recurrent pericarditis. The study showed significant reductions in both pericarditis pain…

Read More

Pomerantz Law Firm Investigates Potential Securities Claims: Business and Professional Services Sector under Scrutiny

Pomerantz LLP Investigates Ibotta, Inc. on Behalf of Investors: What Does This Mean for You and the World? New York, NY – In a recent press release, Pomerantz LLP, a leading securities law firm, announced that it is investigating potential securities fraud claims against Ibotta, Inc. (“Ibotta” or the “Company”) (NYSE:IBTA) on behalf of investors….

Read More

Vivos Therapeutics Successfully Closes $4 Million Private Placement

Vivos Therapeutics Closes $4 Million Private Placement Littleton, Colo., Nov. 02, 2023 (GLOBE NEWSWIRE) — Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS) Vivos Therapeutics, a medical technology company specializing in developing innovative treatments for patients with dentofacial abnormalities, mild-to-moderate obstructive sleep apnea (OSA), and snoring in adults, has announced the successful closure of…

Read More